Parsey Merdad

Parsey Merdad is listed in filings as Director at ArriVent BioPharma, Inc.. This profile follows SEC Form 4 activity through Jun 22, 2026, including 6 public disclosures. Recent filings connect the profile to ArriVent BioPharma, Inc. (AVBP) and Ardelyx, Inc. (ARDX). The current snapshot covers public activity from Apr 29, 2025 to Jun 22, 2026. Reported amounts are shown as $430.5K to $385.8K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.